

Clinical Symposium

New treatments in advanced prostate cancer

Speaker: Sara Merler
Switzerland

Prostate cancer is the most frequently diagnosed cancer in adult men. Medical treatments are rapidly evolving, leading to advances in systemic therapies that were once only used in more advanced stages (such as castration-resistant prostate cancer) but, in recent years, also for hormone-sensitive or even high-risk localized diseases.

Moreover, for a long time, treatments were “only” based on hormone therapies or chemotherapies, while more recently, the way has also been opened to PARP inhibitors and radiometabolic treatments.

In addition, therapies targeting bone metabolism also play an essential role in this disease.

We will, therefore, discuss these developments, in what setting they occurred, and how to handle these drugs. In particular, we will focus on the differences within the same drug class, the potential drug interactions, and the toxicity profile.

Join us to discuss this topic!